Streetbeat News

Equity Actions

CLDI

Calidi Biotherapeutics (NYSE:CLDI) has launched a new subsidiary, Nova Cell, and announced a $2 million investment from Dr. Ronald Rigor. Dr. Rigor also invested an additional $1 million in Calidi, purchasing CLDI stock at a discount and warrants at a premium. He joins Calidi's Scientific and Medical Advisory Board.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:02 pm

CAN

L

Loews Corp (NYSE:L) reported strong Q2 2024 results with net income of $369 million and EPS of $1.67. Revenues grew to $4.27 billion. CNA Financial Corp (NYSE:CAN) and Boardwalk Pipelines segments showed significant growth, while Loews Hotels saw a decline. CEO James Tisch will retire at the end of 2024, with Benjamin Tisch named as his successor. Loews shares were up 6.13% premarket.

Portfolio Pulse from Akanksha Bakshi

July 29, 2024 | 12:52 pm

CCK

Crown Holdings, Inc. (NYSE:CCK) has authorized a $2 billion share repurchase program through the end of 2027, replacing the previous authorization from December 2021. This move highlights the company's strong financial position and commitment to returning cash to shareholders.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:45 pm

VATE

INNOVATE Corp. (NYSE:VATE) has extended the effective date for its 1-for-10 reverse stock split to August 8, 2024. The split aims to increase the per share market price to meet NYSE's minimum bid price requirement. Trading on a split-adjusted basis will begin on August 9, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:43 pm

NRXP

NRx Pharmaceuticals announced that a Utah arbitrator denied Streeterville Capital's petition to prevent the spinoff of 49% of HOPE Therapeutics shares to NRx shareholders and to stop NRx from selling additional shares. The spinoff aims to provide value to NRx shareholders and potentially list HOPE Therapeutics on a national exchange.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:36 pm

NDAQ

Nasdaq, Inc. (NDAQ) announced the pricing of a secondary offering of 41,604,207 shares at $65.30 per share by Argus Seller, LP, an affiliate of Thoma Bravo, L.P. The offering is expected to close on July 30, 2024. Nasdaq will not receive any proceeds from this sale. Additionally, Nasdaq will repurchase 1,200,000 shares from the Selling Stockholder as part of its existing share repurchase program.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:34 pm

JPM

WEX

WEX Inc. has entered into a $300 million accelerated share repurchase agreement with JPMorgan Chase under its existing $1.05 billion repurchase authorization.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:33 pm

LIDR

AEye has entered into a common stock purchase agreement with New Circle Principal Investments, allowing the company to sell up to $50 million of common stock over a 36-month term.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:03 pm

NLSP

NLS Pharmaceutics and Kadimastem have entered into a binding term sheet for a transaction where Kadimastem will become a wholly owned subsidiary of NLS. Kadimastem's shareholders will hold 85% of the issued and outstanding shares of the merged company.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 11:08 am

NOG

Northern Oil and Gas (NOG) plans to increase its Q3 dividend by 5% to $0.42 per share. The company repurchased 895,076 shares in Q2 2024 and 1,444,432 shares in H1 2024, allocating $55 million to share repurchases and $80 million to dividends year-to-date. NOG's Board approved a new $150 million stock repurchase authorization in July 2024.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 11:08 am